PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · IEX Real-Time Price · USD
2.040
+0.010 (0.49%)
May 24, 2024, 4:00 PM EDT - Market closed

Company Description

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.

It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.

PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals logo
Country United States
Founded 2013
IPO Date Sep 25, 2020
Industry Biotechnology
Sector Healthcare
Employees 63
CEO Dr. David H. Mack Ph.D.

Contact Details

Address:
One Research Way
Princeton, New Jersey 08540
United States
Phone (609) 642-6664
Website pmvpharma.com

Stock Details

Ticker Symbol PMVP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001699382
CUSIP Number 69353Y103
ISIN Number US69353Y1038
Employer ID 46-3218129
SIC Code 2834

Key Executives

Name Position
Dr. David H. Mack Ph.D. Co-Founder, Chief Executive Officer, President and Director
Dr. Arnold J. Levine Ph.D. Co-Founder, Director and Member of Scientific Advisory Board
Dr. Thomas E. Shenk Ph.D. Co-Founder and Member of Scientific Advisory Board
Michael Carulli Chief Financial Officer
Robert Ticktin General Counsel, Head of Operations and Company Secretary
Tim Smith Senior Vice President and Head of Corporate Development and Investor Relations
Crystal Zuckerman Vice President of Human Resources
Dr. Binh Vu Ph.D. Senior Vice President of Drug Discovery and CMC
Dr. Deepika Jalota Pharm.D. Chief Development Officer
Dr. Marc Fellous M.D. Senior Vice President and Head of Clinical Development and Medical Affairs

Latest SEC Filings

Date Type Title
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 24, 2024 ARS Filing
Apr 24, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2024 DEF 14A Other definitive proxy statements
Apr 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals